Newbridge Financial Services Group’s ADMA Biologics ADMA Stock Holding History

Newbridge Financial Services Group’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.37K	Hold	1,000	–	–	﹤0.01%	879
2026 Q1	$9.01K	Hold	1,000	–	–	﹤0.01%	812
2025 Q4	$18.2K	Hold	1,000	–	–	﹤0.01%	660
2025 Q3	$14.7K	Hold	1,000	–	–	﹤0.01%	815
2025 Q2	$18.2K	Hold	1,000	–	–	﹤0.01%	745
2025 Q1	$19.8K	Hold	1,000	–	–	﹤0.01%	545
2024 Q4	$17.1K	Buy	+1,000	New	+$18.8K	﹤0.01%	635
2024 Q3	–	Sell	-1,000	Closed	-$11.2K	–	668
2024 Q2	$11.2K	Buy	+1,000	New	+$8.39K	﹤0.01%	688
2021 Q4	–	Sell	-46,050	Closed	-$52K	–	1395
2021 Q3	$52K	Buy	+46,050	New	+$64.5K	0.03%	402

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Newbridge Financial Services Group's ADMA Position: Q2 2026 in Review

Newbridge Financial Services Group held its ADMA Biologics (ADMA) position steady in Q2 2026 at 1,000 shares worth $8.37K. The position accounts for ﹤0.01% of the portfolio, ranked #879.

Newbridge Financial Services Group first reported a position in ADMA in Q3 2021 and has held it in 9 quarters since. The position peaked at $52K in Q3 2021. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Newbridge Financial Services Group held 1,000 shares of ADMA Biologics worth $8.37K as of Q2 2026.
Newbridge Financial Services Group left its ADMA Biologics share count unchanged in Q2 2026.
ADMA Biologics made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q2 2026, its #879 holding.
Newbridge Financial Services Group first reported a position in ADMA Biologics in Q3 2021 and has held it in 9 quarters since.
Newbridge Financial Services Group's ADMA Biologics position peaked at $52K in Q3 2021.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Newbridge Financial Services Group's 13F filing for Q2 2026, filed 14 Aug 2026.